Do you want to read an article? Please log in or register.
Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience
Retinal Diseases
COMMENTED
Related content
Retinal Diseases
Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy
Front Pharmacol
Fasler K, Gunzinger JM, Barthelmes D, Zweifel SA
doi: 10.3389/fphar.2021.675295
Retinal Diseases
Optical Coherence Tomography Parameters as Predictors of Treatment Response to Eplerenone in Central Serous Chorioretinopathy
J Clin Med.
Borrelli E, Zuccaro B, Zucchiatti I, Parravano M, Querques L, Costanzo E, Sacconi R, Prascina F, Scarinci F, Bandello F, Querques G
doi: 10.3390/jcm8091271.Visit the original publication at ncbi.nlm.nih.gov
Retinal Diseases
Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial
Ophthalmology.
van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF
doi: 10.1016/j.ophtha.
Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy
JAMA Ophthalmol.
van Dijk EH, Schellevis RL, van Bergen MG, Breukink MB, Altay L, Scholz P, Fauser S, Meijer OC, Hoyng CB, den Hollander AI, Boon CJ, de Jong EK
doi: 10.1001/
COMMENTED
Retinal Diseases
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial
★ 2
Recommended and commented by
Prof. Dr emer. Josef Flammer, Faculty Member
★ 3
Recommended by
Dr Katarzyna Konieczka, Faculty Member
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Lancet.
Lotery A, Sivaprasad S, O'Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T, Rogers CA, Reeves BC, VICI trial investigators
doi: 10.1016/S0140-6736(19)32981-2.
Further Publications
Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial
Am J Ophthalmol
van Rijssen TJ, van Dijk EHC, Tsonaka R, Feenstra HMA, Dijkman G, Peters PJH, Diederen RMH, Hoyng CB, Schlingemann RO, Boon CJF
doi: 10.1016/j.ajo.2021.06.020
Retinal Diseases
Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy
Ophthalmology.
Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, Yannuzzi NA, Patel S, Chen KC, Yu S, Stoffels G, Spaide RF, Freund KB, Yannuzzi LA
doi: 10.1016/j.ophtha.2018.12.048.
COMMENTED
Role of the Complement System in Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study
JAMA Ophthalmol.
Schellevis RL, van Dijk EHC, Breukink MB, Altay L, Bakker B, Koeleman BPC, Kiemeney LA, Swinkels DW, Keunen JEE, Fauser S, Hoyng CB, den Hollander AI, Boon CJF, de Jong EK
doi: 10.1001/jamaophthalmol.
COMMENTED
Retinal Diseases
The Effect of Selective Retina Therapy with Automatic Real-Time Feedback-Controlled Dosimetry for Chronic Central Serous Chorioretinopathy: A Randomized, Open-Label, Controlled Clinical Trial
★ 1
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
J Clin Med
Lee JY, Kim MH, Jeon SH, Lee SH, Roh YJ
doi: 10.3390/jcm10194295